Patents Assigned to Roche Palo Alto LLC
  • Quinoline inhibitors of HCV polymerase
    Patent number: 8026253
    Abstract: Compounds having the formula I wherein wherein R1, R2, R3, R4, X1, X2, X3 and X4 and as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: September 27, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Javier de Vicente Fidalgo, Jim Li, Ryan Craig Schoenfeld, Francisco Xavier Talamas, Joshua Paul Gergely Taygerly
  • Pyrrolopyrazinyl urea kinase inhibitors
    Patent number: 8012974
    Abstract: The present invention relates to the use of novel pyrrolopyrazinyl urea derivatives of Formula I, wherein the variables R1, R2, R3, R4, and R5 are defined as described herein, which inhibit JAK and are useful for the treatment of auto-immune and inflammatory diseases.
    Type: Grant
    Filed: December 3, 2009
    Date of Patent: September 6, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Joe Timothy Bamberg, Johannes Cornelius Hermann, Remy Lemoine, Michael Soth
  • Methods of using diaminopyrimidine P2Xand P2Xreceptor modulators for treatment of respiratory and gastrointestinal diseases
    Patent number: 8008313
    Abstract: Methods for treating respiratory and gastrointestinal diseases mediated by a P2X3 and/or a P2X2/3 receptor antagonist, the methods comprising administering to a subject in need thereof an effective amount of a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein D, X, Y, R1, R2, R3, R4, R5, R6, R7 and R8 are as defined herein.
    Type: Grant
    Filed: August 25, 2006
    Date of Patent: August 30, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Chris Allen Broka, David Scott Carter, Michael Patrick Dillon, Anthony P. D. W. Ford, Ronald Charles Hawley, Alam Jahangir, Amy Geraldine Moore, Daniel Warren Parish
  • Process for synthesis of phenoxy diaminopyrimidine derivatives
    Patent number: 8003788
    Abstract: A method for preparing a compound of formula k or a salt or solvate thereof, wherein R1 is as defined herein, the method comprising treating a compound of formula j or a salt or solvate thereof, with ammonia, to form the compound of formula k.
    Type: Grant
    Filed: October 4, 2007
    Date of Patent: August 23, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Charles Alois Dvorak, Keena Lynn Green, Gary R. Lee
  • Antibodies against human IL17 and uses thereof
    Patent number: 8003099
    Abstract: An antibody binding to IL-17 characterized by binding to the same IL-17 epitope to which monoclonal antibody 3C1 binds, and being of human IgG1 isotype modified in the hinge region at amino acid position 216-240, preferably at amino acid position 220-240, between CH1 and CH2 and/or in the second inter-domain region at amino acid position 327-331 between CH2 and CH3 has advantageous properties for the treatment of inflammatory diseases.
    Type: Grant
    Filed: September 29, 2009
    Date of Patent: August 23, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Johannes Auer, Nikolaos Dimoudis, Guy Georges, Petra Hanke, Hendrik Knoetgen, Ekkehard Moessner, Claire Louise Langrish
  • Arylpiperazine derivatives and uses thereof
    Patent number: 7998963
    Abstract: Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein Ar is indolyl, indazolyl or dihydroindolyl, and R1, R2, R3 and R4 are as defined herein. Also provided are pharmaceutical compositions, methods of using the compounds in the treatment of depressive, anxiolytic and other disorders associated with inhibition of the reuptake of norepinephrine, serotonin, and dopamine, and methods of preparing the compounds.
    Type: Grant
    Filed: February 12, 2009
    Date of Patent: August 16, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: David Scott Carter, Matthew C. Lucas, Ryan Craig Schoenfeld, Robert James Weikert
  • Non-nucleoside reverse transcriptase inhibitors
    Patent number: 7998969
    Abstract: The present invention provides for compounds useful for treating an HIV infection, or preventing an HIV infection, or treating AIDS or ARC. The compounds of the invention are of formula I wherein R1, R2, R3, R4, R5a, R5b, R6a, R6b and X are as herein defined. Also disclosed in the present invention are methods of treating an HIV infection with compounds defined herein and pharmaceutical compositions containing said compounds.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: August 16, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Denis John Kestesz, Christine E. Brotherton-Pleiss, Minmin Yang
  • Liquid Pharmaceutical Formulations of Palonosetron
    Publication number: 20110192493
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Application
    Filed: April 14, 2011
    Publication date: August 11, 2011
    Applicants: Helsinn Healthcare S.A., Roche Palo Alto LLC
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Enrico Braglia, Riccardo Braglia, Andrew Miksztal, Thomas Malefyt, Kathleen M. Lee
  • Triazole-substituted arylamides as P2Xand P2Xantagonists
    Patent number: 7989637
    Abstract: Compounds of the formula I: or a pharmaceutically acceptable salt thereof, wherein, R1 is optionally substituted triazolyl, and R2, R3, R4, R5, R6, R7 and R8 are as defined herein. Also disclosed are methods of using the compounds for treating diseases associated with P2X3 and/or a P2X2/3 receptor antagonists and methods of making the compounds.
    Type: Grant
    Filed: December 17, 2008
    Date of Patent: August 2, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Li Chen, Michael Patrick Dillon, Lichun Feng, Ronald Charles Hawley, Minmin Yang
  • Tetralin and indane derivatives and uses thereof
    Patent number: 7981923
    Abstract: Compounds of the formula I, II or III: or pharmaceutically acceptable salts thereof, wherein m, n, q, Ar, R1, R2, R3, R4 and R5 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formulas I-III.
    Type: Grant
    Filed: January 26, 2010
    Date of Patent: July 19, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Ralph New Harris, III, James M. Kress, David Bruce Repke, Russell Stephen Stabler
  • Tetrazole-substituted aryl amide derivatives and uses thereof
    Patent number: 7981914
    Abstract: Compounds of the formula: wherein R1, R2, Ar1, Ar2, and n are as defined herein. Also provided are pharmaceutical compositions, methods of using, and methods of preparing the subject compounds.
    Type: Grant
    Filed: October 1, 2008
    Date of Patent: July 19, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Daisy Joe Du Bois, Todd Richard Elworthy, Hans Maag, Sunil Sahdeo
  • Liquid pharmaceutical formulations of palonosetron
    Patent number: 7960424
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: June 14, 2011
    Assignees: Helsinn Healthcare S.A., Roche Palo Alto LLC
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Enrico Braglia, Riccardo Braglia, Andrew Miksztal, Thomas Malefyt, Kathleen M. Lee
  • Conjugate of an antibody against CCR5 and an antifusogenic peptide
    Patent number: 7951920
    Abstract: The current invention is related to a conjugate comprising one or more antifusogenic peptides and an anti-CCR5 antibody (mAb CCR5) characterized in that one to eight antifusogenic peptides are each conjugated to one terminus of the heavy and/or light chains of the anti-CCR5 antibody and to the pharmaceutical use of the conjugate.
    Type: Grant
    Filed: August 17, 2007
    Date of Patent: May 31, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Michael Brandt, Stephan Fischer, Erhard Kopetzki, Suryanarayana Sankuratri, Ralf Schumacher
  • HETEROCYCLIC ANTIVIRAL COMPOUNDS
    Publication number: 20110123490
    Abstract: Compounds having the formula I wherein R1, R2, R3, R4, R5, Ra, Rb, Rc, Rd and n are as defined herein are Hepatitis C virus NS5b polymerase inhibitors. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Application
    Filed: December 14, 2010
    Publication date: May 26, 2011
    Applicant: Roche Palo Alto LLC
    Inventors: RYAN CRAIG SCHOENFELD, Leanna Renee Staben, Francisco Xavier Talamas
  • HETEROCYCLIC ANTIVIRAL COMPOUNDS
    Publication number: 20110123489
    Abstract: Compounds having the formula I wherein wherein R1, R2 and R3 are as defined herein are Hepatitis C virus NS5b polymerase inhibitors with improved bioavailability. Also disclosed are compositions and methods for treating an HCV infection and inhibiting HCV replication.
    Type: Application
    Filed: November 19, 2010
    Publication date: May 26, 2011
    Applicant: Roche Palo Alto LLC
    Inventor: Joshua Paul Gergely Taygerly
  • Liquid pharmaceutical formulations of palonosetron
    Patent number: 7947725
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Grant
    Filed: March 24, 2006
    Date of Patent: May 24, 2011
    Assignees: Helsinn Healthcare S.A., Roche Palo Alto LLC
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Enrico Braglia, Riccardo Braglia, Andrew Miksztal, Thomas Malefyt, Kathleen M. Lee
  • Non-nucleoside reverse transcriptase inhibitors
    Patent number: 7947709
    Abstract: Compounds of formula I, wherein R1, R2, R3, X and Ar, are as defined herein or pharmaceutically acceptable salts thereof, inhibit HIV-1 reverse transcriptase and afford a method for prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC. The present invention also relates to compositions containing compounds of formula I useful for the prevention and treatment of HIV-1 infections and the treatment of AIDS and/or ARC.
    Type: Grant
    Filed: June 20, 2008
    Date of Patent: May 24, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Todd Richard Elworthy, Joan Heather Hogg, Joshua Kennedy-Smith, Counde O'Yang, Mark Smith, Zachary Kevin Sweeney, Jeffrey Wu
  • Liquid pharmaceutical formulations of palonosetron
    Patent number: 7947724
    Abstract: The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.
    Type: Grant
    Filed: July 21, 2005
    Date of Patent: May 24, 2011
    Assignees: Helsinn Healthcare S.A., Roche Palo Alto LLC
    Inventors: Giorgio Calderari, Daniele Bonadeo, Roberta Cannella, Enrico Braglia, Riccardo Braglia, Andrew Miksztal, Thomas Malefyt, Kathleen M. Lee
  • Btk protein kinase inhibitors
    Patent number: 7943618
    Abstract: This application discloses pyridine and pyrimidine compounds according to formula I wherein R1, R2, R3, R4, R5, X1 and A are as described herein which inhibit Btk. The compounds disclosed herein are useful to modulate the activity of Btk and treat diseases associated with excessive Btk activity. The compounds are further useful to treat inflammatory and auto immune diseases associated with aberrant B-cell proliferation such as rheumatoid arthritis. Also disclosed are compositions containing compounds of formula I and at least one carrier, diluent or excipient.
    Type: Grant
    Filed: October 23, 2008
    Date of Patent: May 17, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Nolan James Dewdney, Rama K. Kondru, Yan Lou, Michael Soth, Tobias Gabriel
  • Ruthenium complexes as catalysts for metathesis reactions
    Patent number: 7939668
    Abstract: The invention relates to novel metathesis catalysts of the formula a process for making the same and their use in metathesis reactions such as ring closing or cross metathesis. The invention further relates to a process for the manufacture of a macrocyclic compound of formula VII which have the potential to be useful as HCV protease inhibitors.
    Type: Grant
    Filed: April 10, 2009
    Date of Patent: May 10, 2011
    Assignee: Roche Palo Alto LLC
    Inventors: Kurt Puentener, Michelangelo Scalone